المؤلفون: Puig, Noemí, Contreras, María-Teresa, Agulló, Cristina, Martínez-López, Joaquín, Oriol, Albert, Blanchard, María-Jesús, Ríos, Rafael, Martín, Jesús, Iñigo, María-Belén, Sureda, Anna, Hernández, Miguel-Teodoro, de la Rubia, Javier, González-Calle, Verónica, Krsnik, Isabel, Cabañas, Valentín, Palomera, Luis, Moraleda, José-María, Bargay, Joan, Cedena, María-Teresa, Paiva, Bruno, Rosiñol, Laura, Bladé, Joan, San Miguel, Jesús, Lahuerta, Juan-José, Mateos, María-Victoria

مصطلحات موضوعية: Antibodies, Monoclonal, Hematopoietic Stem Cell Transplantation, Humans, Immunoglobulin Light Chains, Mass Spectrometry, Multiple Myeloma, Transplantation, Autologous

الوصف: Monitoring of the monoclonal protein (M-protein) by electrophoresis and/or immunofixation (IFE) has long been used to assess treatment response in multiple myeloma (MM). However, with the use of highly effective therapies, the M-protein becomes frequently undetectable, and more sensitive methods had to be explored. We applied IFE and mass spectrometry (EXENT&FLC-MS) in serum samples from newly diagnosed MM patients enrolled in the PETHEMA/GEM2012MENOS65 obtained at baseline (n = 223), and after induction (n = 183), autologous stem cell transplantation (n = 173), and consolidation (n = 173). At baseline, the isotypes identified with both methods fully matched in 82.1% of samples; in the rest but 2 cases, EXENT&FLC-MS provided additional information to IFE with regards to the M-protein(s). Overall, the results of EXENT&FLC-MS and IFE were concordant in >80% of cases, being most discordances due to EXENT&FLC-MS+ but IFE- cases. After consolidation, IFE was not able to discriminate 2 cohorts with different median progression-free survival (PFS), but EXENT&FLC-MS did so; furthermore, among IFE- patients, EXENT&FLC-MS identified 2 groups with significantly different median PFS (P = .0008). In conclusion, compared with IFE, EXENT&FLC-MS is more sensitive to detect the M-protein of patients with MM, both at baseline and during treatment, and provides a more accurate prediction of patients' outcome. This trial was registered at www.clinicaltrials.gov as #NCT01916252.

وصف الملف: application/pdf

العلاقة: http://hdl.handle.net/10668/20250Test; PMC9198943; https://doi.org/10.1182/bloodadvances.2021006762Test; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9198943/pdfTest

الإتاحة: https://doi.org/10.1182/bloodadvances.2021006762Test
http://hdl.handle.net/10668/20250Test
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9198943/pdfTest

المؤلفون: Puig, Noemi, Hernández, Miguel T, Rosiñol, Laura, González, Esther, de Arriba, Felipe, Oriol, Albert, González-Calle, Verónica, Escalante, Fernando, de la Rubia, Javier, Gironella, Mercedes, Ríos, Rafael, García-Sánchez, Ricarda, Arguiñano, José M, Alegre, Adrián, Martín, Jesús, Gutiérrez, Norma C, Calasanz, María J, Martín, María L, Couto, María Del Carmen, Casanova, María, Arnao, Mario, Pérez-Persona, Ernesto, Garzón, Sebastián, González, Marta S, Martín-Sánchez, Guillermo, Ocio, Enrique M, Coleman, Morton, Encinas, Cristina, Vale, Ana M, Teruel, Ana I, Cortés-Rodríguez, María, Paiva, Bruno, Cedena, M Teresa, San-Miguel, Jesús F, Lahuerta, Juan J, Bladé, Joan, Niesvizky, Ruben, Mateos, María-Victoria

مصطلحات موضوعية: Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Clarithromycin, Dexamethasone, Female, Hematopoietic Stem Cell Transplantation, Humans, Lenalidomide, Male, Multiple Myeloma, Transplantation, Autologous, Treatment Outcome

الوصف: Although case-control analyses have suggested an additive value with the association of clarithromycin to continuous lenalidomide and dexamethasone (Rd), there are not phase III trials confirming these results. In this phase III trial, 286 patients with MM ineligible for ASCT received Rd with or without clarithromycin until disease progression or unacceptable toxicity. The primary endpoint was progression-free survival (PFS). With a median follow-up of 19 months (range, 0-54), no significant differences in the median PFS were observed between the two arms (C-Rd 23 months, Rd 29 months; HR 0.783, p = 0.14), despite a higher rate of complete response (CR) or better in the C-Rd group (22.6% vs 14.4%, p = 0.048). The most common G3-4 adverse events were neutropenia [12% vs 19%] and infections [30% vs 25%], similar between the two arms; however, the percentage of toxic deaths was higher in the C-Rd group (36/50 [72%] vs 22/40 [55%], p = 0.09). The addition of clarithromycin to Rd in untreated transplant ineligible MM patients does not improve PFS despite increasing the ≥CR rate due to the higher number of toxic deaths in the C-Rd arm. Side effects related to overexposure to steroids due to its delayed clearance induced by clarithromycin in this elderly population could explain these results. The trial was registered in clinicaltrials.gov with the name GEM-CLARIDEX: Ld vs BiRd and with the following identifier NCT02575144. The full trial protocol can be accessed from ClinicalTrials.gov. This study received financial support from BMS/Celgene.

وصف الملف: application/pdf

العلاقة: http://hdl.handle.net/10668/17818Test; PMC8139975; https://www.nature.com/articles/s41408-021-00490-8.pdfTest; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139975/pdfTest

الإتاحة: https://doi.org/10.1038/s41408-021-00490-8Test
http://hdl.handle.net/10668/17818Test
https://www.nature.com/articles/s41408-021-00490-8.pdfTest
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139975/pdfTest

المؤلفون: Solves, Pilar, Marco-Ayala, Javier, Sanz, Miguel Ángel, Gómez-Seguí, Inés, Balaguer-Roselló, Aitana, Facal, Ana, Villalba, Marta, Montoro, Juan, Sanz, Guillermo, de la Rubia, Javier, Sanz, Jaime

المصدر: Journal of Clinical Medicine; May2023, Vol. 12 Issue 10, p3467, 10p

مصطلحات موضوعية: HEMATOPOIETIC stem cell transplantation, CORD blood transplantation, BLOOD transfusion

مستخلص: Introduction: Transfusion plays a main role in supportive treatment for patients who receive an allogeneic hematopoietic stem cell transplantation (HSCT). In this study, we compare the transfusion requirements of patients undergoing different modalities of HSCT according to different time periods. The objective is to assess the evolution of HSCT transfusion requirements over time, from a single institution. Methods: The clinical charts and transfusion records of patients who underwent HSCT of different modalities at La Fe University Hospital during a twelve-year period were reviewed (2009–2020). For analysis, we divided the overall time into three periods: 1 from 2009 to 2012, 2 from 2013 to 2016 and 3 from 2017 to 2020. The study included 855 consecutive adult HSCT: 358 HLA-matched related donors (MRD), 134 HLA-matched unrelated donors (MUD), 223 umbilical cord blood transplantation (UCBT) and 140 haploidentical transplants (Haplo-HSCT). Results: There were no significant differences in RBC and PLT requirements or transfusion independence among the three time periods for MUD and Haplo-HSCT. However, the transfusion burden increased significantly for MRD HSCT during the 2017–2020 period. Conclusion: despite HSCT modalities having evolved and changed over time, overall transfusion requirements have not significantly decreased and continue to be a cornerstone of transplantation-supportive care. [ABSTRACT FROM AUTHOR]

: Copyright of Journal of Clinical Medicine is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Lazzari, Lorenzo, Balaguer-Roselló, Aitana, Montoro, Juan, Greco, Raffaella, Hernani, Rafael, Lupo-Stanghellini, Maria Teresa, Villalba, Marta, Giglio, Fabio, Facal, Ana, Lorentino, Francesca, Guerreiro, Manuel, Bruno, Alessandro, Pérez, Ariadna, Xue, Elisabetta, Clerici, Daniela, Piemontese, Simona, Piñana, José Luis, Sanz, Miguel Ángel, Solano, Carlos, de la Rubia, Javier, Ciceri, Fabio, Peccatori, Jacopo, Sanz, Jaime

المساهمون: Lazzari, Lorenzo, Balaguer-Roselló, Aitana, Montoro, Juan, Greco, Raffaella, Hernani, Rafael, Lupo-Stanghellini, Maria Teresa, Villalba, Marta, Giglio, Fabio, Facal, Ana, Lorentino, Francesca, Guerreiro, Manuel, Bruno, Alessandro, Pérez, Ariadna, Xue, Elisabetta, Clerici, Daniela, Piemontese, Simona, Piñana, José Lui, Sanz, Miguel Ángel, Solano, Carlo, de la Rubia, Javier, Ciceri, Fabio, Peccatori, Jacopo, Sanz, Jaime

مصطلحات موضوعية: Adult, Cyclophosphamide, Humans, Mycophenolic Acid, Retrospective Studies, Sirolimus, Transplantation Conditioning, Unrelated Donors, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Leukemia, Myeloid, Acute

الوصف: Post-transplant cyclophosphamide (PTCy) has emerged as a promising graft-versus-host disease (GvHD) prophylaxis in allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, no studies have reported the efficacy of a GvHD prophylaxis based on PTCy with sirolimus (Sir-PTCy) in patients with acute myeloid leukemia (AML). In this retrospective study, we analyze the use of sirolimus in combination with PTCy, with or without mycophenolate mofetil (MMF), on 242 consecutive adult patients with AML undergoing a myeloablative first allo-HSCT from different donor types, in three European centers between January 2017 and December 2020. Seventy-seven (32%) patients received allo-HSCT from HLA-matched sibling donor, 101 (42%) from HLA-matched and mismatched unrelated donor, and 64 (26%) from haploidentical donor. Except for neutrophil and platelet engraftment, which was slower in the haploidentical cohort, no significant differences were observed in major transplant outcomes according to donor type in univariate and multivariate analysis. GvHD prophylaxis with Sir-PTCy, with or without MMF, is safe and effective in patients with AML undergoing myeloablative allo-HSCT, resulting in low rates of transplant-related mortality, relapse/progression, and acute and chronic GvHD in all donor settings.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/35680995; info:eu-repo/semantics/altIdentifier/wos/WOS:000808391500001; volume:57; issue:9; firstpage:1389; lastpage:1398; numberofpages:10; journal:BONE MARROW TRANSPLANTATION; http://hdl.handle.net/20.500.11768/132811Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85131605087

الإتاحة: https://doi.org/20.500.11768/132811Test
https://doi.org/10.1038/s41409-022-01725-3Test
https://hdl.handle.net/20.500.11768/132811Test

المؤلفون: Solana-Altabella, Antonio, Megías-Vericat, Juan Eduardo, Ballesta-López, Octavio, Boluda, Blanca, Cano, Isabel, Acuña-Cruz, Evelyn, Rodríguez-Veiga, Rebeca, Torres-Miñana, Laura, Sargas, Claudia, Sanz, Miguel Á., Borrell-García, Carmela, López-Briz, Eduardo, Poveda-Andrés, José Luis, De la Rubia, Javier, Montesinos, Pau, Martínez-Cuadrón, David

المصدر: Cancers; Apr2022, Vol. 14 Issue 8, p1921, 10p

مصطلحات موضوعية: CANCER chemotherapy, RETROSPECTIVE studies, ACQUISITION of data, MEDICAL care costs, MEDICAL care use, CANCER patients, HEALTH insurance reimbursement, MEDICAL records, HOSPITAL care, DESCRIPTIVE statistics, HEMATOPOIETIC stem cell transplantation

مصطلحات جغرافية: SPAIN

مستخلص: Simple Summary: Studies addressing the economic costs and burden of secondary acute myeloid leukemia (sAML) are scarce in the literature. We analyzed this topic in a real-life population of sAML patients between 60–75 years receiving intensive chemotherapy induction. In elderly patients with sAML and intensive regimens, it entails an increase in costs and a longer hospital stay. In these specific patients, almost a third of the time is spent hospitalized after the diagnosis of sAML. There are no studies with this type of population and diagnosis, which gives added value to the results obtained. Pharmacoeconomic studies in patients with AML are being carried out due to the need to evaluate the cost-effectiveness of new oral drugs, therapeutic schemes with higher costs than previous treatments. Background: Information regarding the impact on healthcare systems of secondary acute myeloid leukemia (sAML) is scarce. Methods: A retrospective review of medical charts identified patients aged 60–75 years with sAML between 2010 and 2019. Patient information was collected from diagnosis to death or last follow-up. Outpatient resource use, reimbursement, frequency and duration of hospitalization, and transfusion burden were assessed. Forty-six patients with a median age of 64 years were included. Anthracycline plus cytarabine regimens were the most common induction treatment (39 patients, 85%). The ratio of the total days hospitalized between the total follow-up was 29%, with a sum of 204 hospitalizations (average four/patient; average duration 21 days). The total average reimbursement was EUR 90,008 per patient, with the majority (EUR 77,827) related to hospital admissions (EUR 17,403/hospitalization). Most hospitalizations (163, mean 22 days) occurred in the period before the first allogeneic hematopoietic stem cell transplant (alloHSCT), costing EUR 59,698 per patient and EUR 15,857 per hospitalization. The period after alloHSCT (in only 10 patients) had 41 hospitalizations (mean 21 days), and a mean reimbursement cost of EUR 99,542 per patient and EUR 24,278 per hospitalization. In conclusion, there is a high consumption of economic and healthcare resources in elderly patients with sAML receiving active treatments in Spain. [ABSTRACT FROM AUTHOR]

: Copyright of Cancers is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Ludwig, Heinz, Sonneveld, Pieter, Davies, Faith, Bladé, Joan, Boccadoro, Mario, Cavo, Michele, Morgan, Gareth, de la Rubia, Javier, Delforge, Michel, Dimopoulos, Meletios, Einsele, Hermann, Facon, Thierry, Goldschmidt, Hartmut, Moreau, Philippe, Nahi, Hareth, Plesner, Torben, San-Miguel, Jesús, Hajek, Roman, Sondergeld, Pia, Palumbo, Antonio

المصدر: Ludwig , H , Sonneveld , P , Davies , F , Bladé , J , Boccadoro , M , Cavo , M , Morgan , G , de la Rubia , J , Delforge , M , Dimopoulos , M , Einsele , H , Facon , T , Goldschmidt , H , Moreau , P , Nahi , H , Plesner , T , San-Miguel , J , Hajek , R , Sondergeld , P & Palumbo , A 2014 , ' European perspective on multiple myeloma treatment strategies in 2014 ' , Oncologist , vol. 19 ....

مصطلحات موضوعية: Autologous stem cell transplantation, Consolidation, Elderly patients, Maintenance, Multiple myeloma, Nontransplant setting, Risk stratification, Dexamethasone/administration & dosage, Europe, Humans, Hematopoietic Stem Cell Transplantation, Transplantation, Autologous, Treatment Outcome, Multiple Myeloma/epidemiology, Disease-Free Survival, Aged, Antineoplastic Combined Chemotherapy Protocols/administration & dosage

الوصف: The treatment of multiple myeloma has undergone significant changes and has resulted in the achievement of molecular remissions, the prolongation of remission duration, and extended survival becoming realistic goals, with a cure being possible in a small but growing number of patients. In addition, nowadays it is possible to categorize patients more precisely into different risk groups, thus allowing the evaluation of therapies in different settings and enabling a better comparison of results across trials. Here, we review the evidence from clinical studies, which forms the basis for our recommendations for the management of patients with myeloma. Treatment approaches depend on "fitness," with chronological age still being an important discriminator for selecting therapy. In younger, fit patients, a short three drug-based induction treatment followed by autologous stem cell transplantation (ASCT) remains the preferred option. Consolidation and maintenance therapy are attractive strategies not yet approved by the European Medicines Agency, and a decision regarding post-ASCT therapy should only be made after detailed discussion of the pros and cons with the individual patient. Two- and three-drug combinations are recommended for patients not eligible for transplantation. Treatment should be administered for at least nine cycles, although different durations of initial therapy have only rarely been compared so far. Comorbidity and frailty should be thoroughly assessed in elderly patients, and treatment must be adapted to individual needs, carefully selecting appropriate drugs and doses. A substantial number of new drugs and novel drug classes in early clinical development have shown promising activity. Their introduction into clinical practice will most likely further improve treatment results.

العلاقة: https://portal.findresearcher.sdu.dk/da/publications/8305cbde-5205-4a34-80e1-6c7fd678c62bTest

الإتاحة: https://doi.org/10.1634/theoncologist.2014-0042Test
https://portal.findresearcher.sdu.dk/da/publications/8305cbde-5205-4a34-80e1-6c7fd678c62bTest

المؤلفون: Casanova, Bonaventura, Jarque, Isidro, Gascón, Francisco, Hernández-Boluda, Juan, Pérez-Miralles, Francisco, Rubia, Javier, Alcalá, Carmen, Sanz, Jaime, Mallada, Javier, Cervelló, Angeles, Navarré, Arantxa, Carcelén-Gadea, María, Boscá, Isabel, Gil-Perotin, Sara, Solano, Carlos, Sanz, Miguel, Coret, Francisco, Hernández-Boluda, Juan Carlos, de la Rubia, Javier, Sanz, Miguel Angel

المصدر: Neurological Sciences; Jul2017, Vol. 38 Issue 7, p1213-1221, 9p

مصطلحات موضوعية: MULTIPLE sclerosis treatment, HEMATOPOIETIC stem cell transplantation, IMMUNOTHERAPY, NEURODEGENERATION, DEGENERATION (Pathology), CYTARABINE, AUTOGRAFTS, COMPARATIVE studies, LONGITUDINAL method, RESEARCH methodology, MEDICAL cooperation, RESEARCH, EVALUATION research, TREATMENT effectiveness, THERAPEUTICS

مستخلص: The main objective of our work is to describe the long-term results of myeloablative autologous hematopoietic stem cell transplant (AHSCT) in multiple sclerosis patients. Patients that failed to conventional therapies for multiple sclerosis (MS) underwent an approved protocol for AHSCT, which consisted of peripheral blood stem cell mobilization with cyclophosphamide and granulocyte colony-stimulating factor (G-CSF), followed by a conditioning regimen of BCNU, Etoposide, Ara-C, Melphalan IV, plus Rabbit Thymoglobulin. Thirty-eight MS patients have been transplanted since 1999. Thirty-one patients have been followed for more than 2 years (mean 8.4 years). There were 22 relapsing-remitting multiple sclerosis (RRMS) patients and 9 secondary progressive multiple sclerosis (SPMS) patients. No death related to AHSCT. A total of 10 patients (32.3%) had at least one relapse during post-AHSCT evolution, 6 patients in the RRMS group (27.2%) and 4 in the SPMS group (44.4%). After AHSCT, 7 patients (22.6%) experienced progression of disability, all within SP form. By contrast, no patients with RRMS experienced worsening of disability after a median follow-up of 5.4 years, 60% of them showed a sustained reduction in disability (SRD), defined as the improvement of 1.0 point in the expanded disability status scale (EDSS) sustains for 6 months (0.5 in cases of EDSS ≥ 5.5). The only clinical variable that predicted a poor response to AHSCT was a high EDSS in the year before transplant. AHSCT using the BEAM-ATG scheme is safe and efficacious to control the aggressive forms of RRMS. [ABSTRACT FROM AUTHOR]

: Copyright of Neurological Sciences is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: LUDWIG, HEINZ, AVET-LOISEAU, HERV, BLAD, JOAN, BOCCADORO, MARIO, CAVENAGH, JAMIE, CAVO, MICHELE, DAVIES, FAITH, DE LA RUBIA, JAVIER, DELIMPASI, SOSANA, DIMOPOULOS, MELETIOS, DRACH, JOHANNES, EINSELE, HERMANN, FACON, THIERRY, GOLDSCHMIDT, HARTMUT, HESS, URS, MELLQVIST, ULF-HENRIK, MOREAU, PHILIPPE, SAN-MIGUEL, JESéS, SONDERGELD, PIA, SONNEVELD, PIETER

المصدر: Oncologist; May2012, Vol. 17 Issue 5, following p592-606, 16p, 2 Diagrams, 5 Charts

مصطلحات موضوعية: ANTINEOPLASTIC agents, COMBINATION drug therapy, FRAIL elderly, GENES, HEMATOPOIETIC stem cell transplantation, MULTIPLE myeloma, QUALITY of life, RISK assessment, THALIDOMIDE, DISEASE relapse, PROGNOSIS, THERAPEUTICS

مصطلحات جغرافية: EUROPE

مستخلص: The management of multiple myeloma has undergone profound changes over the recent past as a result of advances in our understanding of the disease biology as well as improvements in treatment and supportive care strategies. Notably, recent years have seen a surge in studies incorporating the novel agents thalidomide, bortezomib, and lenalidomide into treatment for different disease stages and across different patient groups. This article presents an update to a previous review of European treatment practices and is based on discussions during an expert meeting that was convened to review novel agent data published or presented at medical meetings until the end of 2011 and to assess their impact on treatment strategies. [ABSTRACT FROM AUTHOR]

: Copyright of Oncologist is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Puig, Noemí, de la Rubia, Javier, Jarque, Isidro, Salavert, Miguel, Montesinos, Pau, Sanz, Jaime, Martín, Guillermo, Sanz, Guillermo, Cantero, Susana, Lorenzo, Ignacio, Sanz, Miguel A

المصدر: International Journal of Hematology; Aug2007, Vol. 86 Issue 2, p186-192, 7p

مصطلحات موضوعية: ANTI-infective agents, ANTINEOPLASTIC agents, AUTOGRAFTS, BACTEREMIA, FEVER, HEMATOPOIETIC stem cell transplantation, OPPORTUNISTIC infections, PREANESTHETIC medication, DISEASE incidence, RETROSPECTIVE studies

مستخلص: Infectious complications are a major cause of morbidity and mortality in patients who undergo autologous stem cell transplantation (ASCT). We examined 476 patients with hematologic malignancies (401) or solid tumors (75) who underwent ASCT between February 1990 and May 2005. Anti-infectious prophylaxis consisted of different combinations of ciprofloxacin, cotrimoxazole, fluconazole, aerosolized amphotericin B, acyclovir, and intravenous immunoglobulins. Overall, 454 patients (95%) developed fever in the first 60 days after ASCT. In the majority of patients, initial antibiotic therapy consisted of broad-spectrum beta-lactamic with or without amikacin. A glycopeptide was administered as initial therapy in 86 cases. Overall, there were 132 (29%) clinically documented infections (37 pneumonias), 79 (17%) microbiologically documented infections (65 bacteremias), and 243 (54%) fevers of unknown origin. Coagulase-negative staphylococci (18, 25%) and E coli (18, 25%) were the organisms most frequently isolated. The pattern of infection did not change throughout the study except for a significantly higher incidence of bacteremia due to gram-positive bacteria in the first 5 years of the study. Infection-related mortality was 5% (21 cases), with pneumonia the most frequent cause of death. ASCT should be considered a low-risk procedure, although new therapeutic approaches for patients developing severe respiratory infections are still needed. [ABSTRACT FROM AUTHOR]

: Copyright of International Journal of Hematology is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Brunet, Salut, Urbano-Ispizua, Alvaro, Ojeda, Emilio, Ruiz, Dolores, Moraleda, José Ma., Díaz, Miguel Angel, Caballero, Dolores, Bargay, Joan, de la Rubia, Javier, Solano, Carlos, Zuazu, Javier, Diez, José Luis, de la Serna, Javier, Espigado, Idelfonso, Alegre, Adrián, Torres, J. Pio, Jurado, Manuel, Fernández, Manuel, Vivancos, Pilar, Carreras, Enric

المصدر: British Journal of Haematology; Sep2001, Vol. 114 Issue 3, p544-550, 7p, 4 Charts, 2 Graphs

مصطلحات موضوعية: GRAFT versus host disease, HEMATOPOIETIC stem cell transplantation, HEMATOLOGICAL oncology

مستخلص: To assess the influence of graft-versus-host disease (GVHD) on the outcome of patients with advanced haematological malignancies (AHM) who received a primary, unmodified allogeneic peripheral blood progenitor cells transplant (allo-PBT) from a human leucocyte antigen (HLA) identical sibling donor, we analysed 136 patients with myeloid neoplasms (n = 70) or lymphoproliferative disorders (n = 66), transplanted at 19 Spanish institutions. Median age was 35 years (range 1–61). The cumulative incidence of relapse for all patients was 34% (95% CI, 26–42%), 41% (95% CI, 33–49) for patients without GVHD and 14% (95% CI, 3–25) (P = 0·001) for patients with acute and chronic GVHD. After a median follow-up of 11 months (range 2–49), 60 (44%) patients remained alive with an actuarial probability of overall survival and disease-free survival (DFS) at 30 months of 31% (95% CI, 21–41%) and 28% (95% CI, 17–39%) respectively. In patients surviving > 100 d, the low incidence of relapse in those with acute and chronic GVHD led to a DFS of 57% (95% CI, 38–76%) compared with a DFS of 34% (95% CI, 17–51%) in the remaining patients (P = 0·03). Our results indicate a reduced incidence of relapse for patients with AHM receiving an unmodified allo-PBT and developing acute and chronic GVHD, which results in an improved DFS. [ABSTRACT FROM AUTHOR]

: Copyright of British Journal of Haematology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)